1 | All patients in the study will be treated with ocrelizumab | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
2 | Continued Ocrelizumab | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
3 | Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab | [12] Acetate Acetate, Alemtuzumab, Cladribine, Dimethyl fumarate, Fingolimod, Glatiramer, Natalizumab, Ocrelizumab, Ofatumumab, Ponesimod, Rituximab, Teriflunomide | [10] Cladribine
Cladribine
,
Alemtuzumab
,
Rituximab
,
Dimethyl fumarate
,
Ocrelizumab
,
Natalizumab
,
Ofatumumab
,
Fingolimod
,
Teriflunomide
,
Ponesimod
💬 | [7] CD52 CD52, DHODH, ITGA4, KEAP1, MS4A1, RRM1, S1PR1 💬 | [30] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molecules, Chemical carcinogenesis - reactive oxygen species, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Hematopoietic cell lineage, Hepatocellular carcinoma, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Sphingolipid signaling pathway, Ubiquitin mediated proteolysis, Yersinia infection 💬 | [1] 13 13 💬 |
4 | OCRELIZUMAB | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [3] 13 13, 46, 49 💬 |
5 | Ocrelizumab (CinnaGen, Iran) | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
6 | Ocrelizumab (Roche, Switzerland) | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
7 | Ocrelizumab / rhuMAb 2H7 | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 46 46 💬 |
8 | Ocrelizumab 300 mg | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
9 | Ocrelizumab 300mg | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
10 | Ocrelizumab 300mg /10ml | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
11 | Ocrelizumab 300mg/10 ml | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
12 | Ocrelizumab 300mg/10ml | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
13 | Ocrelizumab 500mg | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 46 46 💬 |
14 | Ocrelizumab 600 mg | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
15 | Ocrelizumab at home | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
16 | Ocrelizumab Dose 1 | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
17 | Ocrelizumab Dose 2 and Dose 3 | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
18 | Ocrelizumab IV | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
19 | Ocrelizumab SC | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
20 | Ocrelizumabu 200mg | - | - | - | - | [1] 46 46 💬 |
21 | Ocrelizumabu 50mg | - | - | - | - | [1] 46 46 💬 |
22 | Perfusion of treatment Ocrelizumab | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |
23 | Short-course Ocrelizumab | [1] Ocrelizumab Ocrelizumab | [1] Ocrelizumab
Ocrelizumab
💬 | [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 💬 |